Key result
A 92-year-old female developed amiodarone pulmonary toxicity presenting with dyspnea, dry cough, and interstitial opacities after only five weeks of low-dose amiodarone therapy.
Case Report (n=1)
No
Amiodarone pulmonary toxicity should be considered in elderly patients presenting with dyspnea and interstitial opacities, even after short-term, low-dose use.
Answers are grounded in this paper and cite their sources.
Amiodarone pulmonary toxicity warrants vigilance in elderly AF patients; this case extends awareness but leaves open optimal monitoring strategies.
This is the case of a 92-year-old female who was hospitalized one month prior to admission for symptomatic paroxysmal atrial fibrillation, requiring intravenous amiodarone. Following her previous admission, she was placed on one month of amiodarone 200 mg twice daily, with a one week transition to 200 mg daily. The patient subsequently developed progressive shortness of breath and dry cough over a period of several weeks. Initial imaging showed diffuse bilateral coarse patchy interstitial infiltration on chest X-ray and bibasilar pleural effusions and scattered bilateral opacities on CTA chest. In an elderly patient presenting with dyspnea and dry cough, as well as interstitial opacities on imaging, amiodarone pulmonary toxicity should be considered despite short-term low-dose use.
No takes yet. Share an insight, caveat, or question.
Abigail McDonald (2020) conducted a case report in Amiodarone pulmonary toxicity (n=1). Amiodarone was evaluated on Development of amiodarone pulmonary toxicity. A 92-year-old female developed amiodarone pulmonary toxicity presenting with dyspnea, dry cough, and interstitial opacities after only five weeks of low-dose amiodarone therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: